Identifying immunoregulatory gut bacteria in type 1 diabetes and autoimmunity

识别 1 型糖尿病和自身免疫性疾病中的免疫调节肠道细菌

基本信息

  • 批准号:
    10467123
  • 负责人:
  • 金额:
    $ 42.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-05-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

Abstract It is known that patients with type 1 autoimmune diabetes (T1D) have altered gut microbiota, and potentially pathogenic bacteria, which are increased, have been much studied. However, less is known of the impact on the host immune system, and in particular on immune regulation, of the bacterial species, which are significantly reduced. We hypothesized that the reduced bacterial species are associated with the lack of immune tolerance in T1D, especially the bacterial species that are commonly present in both the gut and oral cavity. Taking advantage of availability of germ free animals and a pure V dispar strain from human oral cavity, we tested this hypothesis by using V. dispar to colonize germ-free (GF) mice and assessed the effect of V. dispar on immune cells. It is intriguing that we found that V. dispar promoted Treg cells in most of the peripheral lymphoid tissues examined and the majority of the Treg cells expressed neuropilin-1 and a higher frequency of the Tregs were IL-10 producers. These in vivo effects of V. dispar could also be mirrored in vitro with direct contact of immune cells to V. dispar. V. dispar induced Tregs are ready to suppress naturally primed diabetogenic T cells in vitro. More importantly, V. dispar ameliorated the severity of insulitis in NOD mice. Further, V. dispar produce high level of short chain fatty acids (SCFAs) acetate and propionate. In addition, V. dispar markedly improved gut permeability. Moreover, the induction of Tregs and IL-10 producers, as well as improvement of gut permeability by V. dispar were found when tested in both GF-NOD and GF-B6 mouse strains, suggesting that V. dispar has a general immune regulatory effect.. Our preliminary data are compelling, and lead us to hypothesize that V. dispar are important in maintaining immune regulation, and hence immune tolerance. We propose the 3 specific aims to test our hypothesis using GF NOD and GF B6 mice, as well as the mouse strains in which dendritic cells or Tregs or short chain fatty acid (SCFA) receptor are specifically targeted (commercially available). Our approach using V. dispar as a model system will also signpost the study of other bacteria species that were markedly reduced in the gut of patients with T1D. If our hypothesis is proved to be correct, our study will help with the design of future novel therapy for T1D and other autoimmune disorders, for which, we will “return“ to human studies.
摘要 已知患有1型自身免疫性糖尿病(T1 D)的患者具有改变的肠道微生物群,并且可能 已经对增加的病原菌进行了大量研究。然而,人们对这种影响知之甚少, 对宿主免疫系统,特别是对细菌物种的免疫调节, 大幅减少。我们假设细菌种类的减少与缺乏 T1 D中的免疫耐受,特别是通常存在于肠道和 口腔利用无菌动物和来自人的纯舞毒菌株的可用性, 口腔,我们通过使用舞毒菌定殖无菌(GF)小鼠来验证这一假设,并评估 舞毒菌对免疫细胞的影响。有趣的是,我们发现舞毒菌在大多数小鼠中促进Treg细胞, 的外周淋巴组织检查和大多数的Treg细胞表达神经纤毛蛋白-1和一个神经纤毛蛋白-2。 IL-10产生者频率较高。舞毒菌的这些体内作用也可能是 反映在体外免疫细胞与舞毒菌的直接接触。舞毒菌诱导的Tvis准备好 在体外抑制天然引发的致糖尿病T细胞。更重要的是,舞毒菌改善了 NOD小鼠的胰岛炎。此外,舞毒菌产生高水平的短链脂肪酸(SCFAs)乙酸酯 和丙酸盐。此外,舞毒菌显著改善肠道通透性。此外, 当测试时,发现V. dispar产生TdR和IL-10,以及肠道通透性的改善 在GF-NOD和GF-B6小鼠品系中,表明舞毒菌具有一般的免疫调节作用, 影响..我们的初步数据是令人信服的,并使我们假设,舞毒蛾是重要的, 维持免疫调节,从而维持免疫耐受。我们提出了三个具体目标,以测试我们的 使用GF NOD和GF B6小鼠,以及其中树突状细胞或T细胞的小鼠品系, 短链脂肪酸(SCFA)受体是特异性靶向(可商购)。我们的方法 使用V. dispar作为模型系统也将标志着对其他细菌物种的研究, T1 D患者的肠道中减少。如果我们的假设被证明是正确的,我们的研究将有助于 设计未来针对T1 D和其他自身免疫性疾病的新型疗法,为此,我们将“回归”人类 问题研究

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Li Wen其他文献

A Naïve Bayesian Multi-label Classification Algorithm with Application to Visualize Text Search Results.
A Nave Bayesian Multi-label Classification Algorithm with Application to Visualize Text Search Results.
阿娜

Li Wen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Li Wen', 18)}}的其他基金

Identifying immunoregulatory gut bacteria in type 1 diabetes and autoimmunity
识别 1 型糖尿病和自身免疫性疾病中的免疫调节肠道细菌
  • 批准号:
    10613570
  • 财政年份:
    2022
  • 资助金额:
    $ 42.31万
  • 项目类别:
Antibody and gut bacteria in obesity and T2D
肥胖和 T2D 中的抗体和肠道细菌
  • 批准号:
    10370392
  • 财政年份:
    2021
  • 资助金额:
    $ 42.31万
  • 项目类别:
Antibody and gut bacteria in obesity and T2D
肥胖和 T2D 中的抗体和肠道细菌
  • 批准号:
    10599318
  • 财政年份:
    2021
  • 资助金额:
    $ 42.31万
  • 项目类别:
Investigating the early development of the immune system and islet autoimmunity later in life
研究生命后期免疫系统的早期发育和胰岛自身免疫
  • 批准号:
    10186469
  • 财政年份:
    2019
  • 资助金额:
    $ 42.31万
  • 项目类别:
Dendritic cells in immuno-metabolic disorder in mouse and man
小鼠和人类免疫代谢紊乱中的树突状细胞
  • 批准号:
    8761742
  • 财政年份:
    2014
  • 资助金额:
    $ 42.31万
  • 项目类别:
Dendritic cells in immuno-metabolic disorder in mouse and man
小鼠和人类免疫代谢紊乱中的树突状细胞
  • 批准号:
    8913163
  • 财政年份:
    2014
  • 资助金额:
    $ 42.31万
  • 项目类别:
Role of TLR9 in beta cell function and diabetes
TLR9 在 β 细胞功能和糖尿病中的作用
  • 批准号:
    8295666
  • 财政年份:
    2012
  • 资助金额:
    $ 42.31万
  • 项目类别:
Role of TLR9 in beta cell function and diabetes
TLR9 在 β 细胞功能和糖尿病中的作用
  • 批准号:
    8639561
  • 财政年份:
    2012
  • 资助金额:
    $ 42.31万
  • 项目类别:
Role of TLR9 in beta cell function and diabetes
TLR9 在 β 细胞功能和糖尿病中的作用
  • 批准号:
    8462243
  • 财政年份:
    2012
  • 资助金额:
    $ 42.31万
  • 项目类别:
Environment, innate immunity and type 1 diabetes
环境、先天免疫和 1 型糖尿病
  • 批准号:
    8478090
  • 财政年份:
    2010
  • 资助金额:
    $ 42.31万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.31万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了